FREQUENCY OF PULMONARY HYPERTENSION IN POST TUBERCULOSIS PATIENTS

AU REHMAN; S HUSSAIN; F ULLAH; M HABIB; S SIKANDAR; MA MASOOD

doi:10.54112/bcsrj.v2024i1.1277

Authors

AU REHMAN Department of Pulmonology, Hayatabad Medical Complex, Peshawar, Pakistan
S HUSSAIN Department of Pulmonology, Hayatabad Medical Complex, Peshawar, Pakistan
F ULLAH Department of Pulmonology, Hayatabad Medical Complex, Peshawar, Pakistan
M HABIB Department of Accidents and Emergency, Chenab Rangers Hospital, Sialkot, Pakistan
S SIKANDAR Population Welfare Department THQ Phalia, Pakistan
MA MASOOD Faiz Rehman Hospital Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1277

Keywords:

Pulmonary Hypertension, Post-Tuberculosis, Frequency, Respiratory Complications, Lung Health, Chronic Disease, Pulmonary Sequelae

Abstract

Pulmonary arterial hypertension (PAH) is a severe complication that can develop in patients with a history of pulmonary tuberculosis (PTB), leading to increased morbidity and mortality. This study aimed to determine the frequency and associated risk factors of PAH in post-TB patients, with a focus on age, gender, BMI, and duration since TB diagnosis. Objective: To assess the frequency of PAH and identify potential risk factors in post-TB patients, providing insights to guide improved screening and follow-up practices. Methods: A cross-sectional study was conducted on 108 post-TB patients at the Department of Pulmonology, Hayatabad Medical Complex, Peshawar from January 2024 to July 2024. PAH was diagnosed using echocardiography, with pulmonary arterial pressure (PAP) thresholds set above 20 mmHg. Data were analyzed to assess associations between PAH and variables including age, gender, BMI, and time since TB diagnosis. Results: The study found a 35.2% prevalence of PAH among post-TB patients. Older age and longer duration since TB diagnosis were significantly associated with higher PAH frequency, while gender and BMI were not significantly associated with PAH risk. Conclusion: It is concluded that PAH is a common complication in post-TB patients, particularly among older individuals and those further removed from their TB diagnosis. These findings underscore the need for routine PAH screening in high-risk post-TB patients to enable timely intervention and improve outcomes.

Downloads

Download data is not yet available.

References

Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev 2019; 1

Kay AW, González Fernández L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev 2020; 8

Goossens SN, Sampson SL, Van Rie A. Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis. Clin Microbiol Rev 2020; 34

Moule MG, Cirillo JD. Mycobacterium tuberculosis Dissemination Plays a Critical Role in Pathogenesis. Front Cell Infect Microbiol. 2020; 10:65.

Kalla IS, Miri A, Seedat F. Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. Afr J Thoracic Crit Care Med 2020; 26:133-7.

Jo YS, Park JH, Lee JK, Heo EY, Chung HS, Kim DK. Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017; 12:2433-43.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53:1801913.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:1801914.

Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018; 36

Butrous G. Pulmonary hypertension; From an orphan disease to a global epidemic. Glob Cardiol Sci Pract. 2020; 2020

Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med. 2018;6:577–579.

Chen Y, Liu C, Lu W, Li M, Hadadi C, Wang EW, et al. Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study. J Thorac Dis. 2016;8:350–358.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. DOI: 10.1183/13993003.01913-2018.

Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021;3099:1–9.

Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:1129–37.

Datta S, Evans CA. Healthy survival after tuberculosis. Lancet Infect Dis. 2019;19:1045–47.

Allwood B, van der Zalm M, Makanda G, Mortimer K, Andre FSA, Uzochukwu E, et al. The long shadow post-tuberculosis. Lancet Infect Dis. 2019;19:1170–71.